Skip to main content
Clinical Trials/JPRN-UMIN000041430
JPRN-UMIN000041430
Recruiting
未知

Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-Analysis - Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-Analysis

Overview

Phase
未知
Intervention
Not specified
Conditions
There is a controversial debate regarding how to treat cardiovascular disease in COVID-19 confirmed patients. Ones documented that ACE inhibitor may increase risk of fatal COVID-19 by serving entry site for this virus, on contrary ones documented that ACEi and/or ARB may be beneficial for Acute Lung Injury and cardiovascular protection.
Sponsor
Faculty of Medicine, Universitas Airlangga
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 16, 2020
End Date
August 16, 2020
Last Updated
2 years ago
Study Type
Others,meta-analysis etc
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The exclusion criteria are (1\) non\-English articles; (2\) review, case\-control studies, case reports, and case series; (3\) studies without full\-text articles; (4\) studies that do not contain primary data in their published articles; and (5\) unpublished records such as conference papers, theses, and patents.

Outcomes

Primary Outcomes

Not specified

Similar Trials